MT1013/MT1013
Phase 1Small molecule
MT1013/MT1013 is one of 28 small molecule programs targeting Secondary Hyperparathyroidism. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
27
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
38 competitors in Secondary Hyperparathyroidism
#DrugCompanyPhaseTrials
1Zemplar
AbbVieApproved
Sensipar
AmgenApproved
Rocaltrol
Alnylam PharmaceuticalsApproved
Deltavit
HHyundai Pharmaceutical Co., LTD.
Approved
Rayaldee
OOrganon and Co
Approved
Parsabiv
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Phase 3
Hectorol
SanofiPhase 3
Zemplar
SanofiApproved
AMG 333
AmgenPhase 3
Hectorol
SanofiApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MT1013/MT1013. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details